HB419 (glibenclamide) in the treatment of diabetes mellitus.
D000328:Adult; D000367:Age Factors; D000368:Aged; D001645:Biguanides / Q000008:administration & dosage* / Q000009:adverse effects; D002747:Chlorpropamide / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D005705:Gallbladder Diseases / Q000150:complications; D005767:Gastrointestinal Diseases / Q000150:complications; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007674:Kidney Diseases / Q000150:complications; D008107:Liver Diseases / Q000150:complications; D008297:Male; D008687:Metformin / Q000008:administration & dosage; D008875:Middle Aged; D010629:Phenformin / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D014044:Tolbutamide / Q000008:administration & dosage; D014508:Urea / Q000008:administration & dosage* / Q000009:adverse effects; D014652:Vascular Diseases / Q000150:complications
D001645:Biguanides; D007004:Hypoglycemic Agents; D013449:Sulfonamides; D014508:Urea; D008687:Metformin; D014044:Tolbutamide; D010629:Phenformin; D002747:Chlorpropamide